Capivasertib Doubles PFS in Some Breast Cancers

In the phase III CAPItello-291 study, the combination of fulvestrant and capivasertib more than doubled progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative breast cancer who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors. The AKT inhibitor could become a treatment option for these patients.